Table 2.
Primary and secondary outcomes of the whole study population
|
IgM-eIVIG |
Treated |
Untreated |
|
|
|---|---|---|---|---|
| n = 40 | n = 39 | OR (95%CI) | p | |
|
Short term mortality |
9 (22%) |
18 (46%) |
0.16 (0.3-0.7) |
0,005* |
|
Total mortality |
17 (44%) |
18 (46%) |
0.46 (0.9-1.8) |
NS |
|
IVH |
9 (22%) |
8 (20%) |
1.17 (0.5-2.7) |
NS |
|
PVL |
3 (7,5%) |
2 (3%) |
2.6 (0.5-14) |
NS |
|
NEC |
2 (6%) |
1 (3%) |
2 (0.4-11) |
NS |
| BDP | 4(10%) | 4 (10%) | 0.97(0.2-4.2) | NS |
*p < 0.05 (IVH: intraventricular hemorrhage, PVL: periventricular leukomalacia, NEC: necrotizing enterocolitis, BPD: bronchopulmonary dysplasia).